Tel:
Fax:
Email:
Creative Biolabs

An Anti-Cancer Drug Could be New Hope for Alzheimer's Disease

Alzheimer's disease (AD) is the most common neurodegenerative disease, occurring primarily in the elderly, and its prevalence is increasing as the average human lifespan increases. Current treatments for AD focus on controlling symptoms and slowing the progression of the disease by targeting the accumulation of beta-amyloid (Aβ) or tau protein plaques in the brain.

AD disrupts the glucose metabolism needed to fuel a healthy brain. Essentially, the metabolic decline robs the brain of energy, which in turn impairs thinking and memory. Recent proteomic studies have also shown that astrocyte and microglia metabolism is significantly disrupted in patients with AD.

Researchers from Stanford University and other institutions collaborated on a research paper. The study shows that blocking indoleamine 2,3-dioxygenase 1 (IDO1) restores glucose metabolism and rescues memory and brain function in astrocytes of the brain in a mouse model of AD. IDO1 inhibitors are currently being developed for the treatment of different types of cancer, suggesting that this drug, developed for the treatment of cancer, has the potential to be a new treatment for neurodegenerative diseases such as AD.

Creative Biolabs offers the following related services to help accelerate the progress of your program.

Our Services Descriptions
AD In Vitro Assay Creative Biolabs has established an advanced platform for Aβ and tau detection. We are committed to providing professional AD in vitro testing services to customers around the world.
AD In Vitro Disease Models Our services cover tissue-based models, cell-based models, molecular-based models, etc. With advanced technology platforms and professional experts, we are confident in offering customer-satisfied services.
AD Drug Discovery Service The development or reuse of drugs that can target different aspects of the pathogenesis of AD has become a hope for the treatment of AD. Creative Biolabs can apply our considerable experience with AD solutions to develop the necessary analytics specific to your neuroscience research project.

An Enzyme Expressed in Astrocytes - IDO1

Lactic acid produced by astrocytes is exported to neurons to fuel mitochondrial respiration and support synaptic activity. Recent studies have shown that IDO1, an enzyme expressed in astrocytes, plays an important role in a number of neurodegenerative diseases, including AD.

IDO1 is the rate-limiting enzyme in the conversion of tryptophan (TRP) to kynurenine (KYN), which acts as a metabolite to cause immunosuppression in inflammatory and tumor environments by interacting with the aromatic hydrocarbon receptor (AhR). IDO1 activity is significantly up-regulated by a wide range of immunogenic stimuli and, in the brain, is expressed in astrocytes and microglia, but not in neurons, and its levels can increase in response to inflammatory stimuli. Overactivation of the KYN pathway in astrocytes results in the inability of astrocytes to produce enough lactate to serve as a source of energy for neurons, thereby disrupting healthy brain metabolism and damaging synapses.

Thus, the team hypothesized that an increase in IDO1 and KYN triggered by the accumulation of Aβ or tau proteins would disrupt healthy brain metabolism and lead to cognitive decline.

For astrocyte related research, we also offer a range of research tools, including but not limited to the following:

Cat. No Product Name Product Category Applications
NCC20-9PZ01 Human Astrocytes Cell
NCL-2105-P182-AM Human Astrocytes, Immortalized Cell
NCC20-9PZ57 Rat Astrocytes derived from Cortex-Hippocampus-Striatum Cell
NCL-2103-P59 iNeu™ Human Astrocytes for Calicum Sensor Assay Cell Calcium Biosensor Assay
NCL-2103-P60 iNeu™ Human Astrocytes for Mitochondrial Sensor Assay Cell Mitochondrial Sensor Assay
NCC20-9PZ02 CocKit™ Astrocyte Growth Medium Kit Kit Cell Culture
NRZP-0423-ZP500 NeuroPro™ Anti-GDNF BBB Shuttle Protein Cell Assay Reagents Cell Assay
NAB-0720-Z2077 NeuroMab™ Rabbit Anti-MANF Monoclonal Antibody (CBP519) Antibody WB; ICC; IF; FC; IP
NAB-08-PZ026 NeuroMab™ Mouse Anti-ABCA1 Monoclonal Antibody (CBP1618) Antibody WB; IHC-P; FC
NAB-08-PZ028 NeuroMab™ Rabbit Anti-ABCG1 Monoclonal Antibody (CBP1619) Antibody ICC; IF; WB
NAB2007FY615 Mouse Anti-GFAP Monoclonal Antibody (CBP2002) Antibody WB; IHC; ICC; IF

IDO1 Inhibitors Tested in AD Mouse Models

IDO1 is well known in oncology, and drugs that inhibit IDO1 activity and KYN production are already undergoing clinical trials in multiple cancer therapies. Therefore, the team tested IDO1 inhibitors using preclinical models - in vitro cell models with Aβ proteins and tau proteins, in vivo mouse models, and in vitro human cells from patients with AD.

  • The brain relies heavily on glucose to drive many processes, so losing the ability to efficiently utilize glucose for metabolism and energy production can lead to metabolic decline, especially cognitive decline. And this study allows us to visualize precisely how the brain's metabolism is affected by neurodegenerative pathologies.
  • IDO1 inhibitors improved glucose metabolism in the mouse hippocampus, repaired defects in astrocyte function, and enhanced their cognitive and spatial memory abilities. Blocking KYN production by inhibiting IDO1 restored the ability of astrocytes to produce lactate to nourish neurons and also rescued behavioral abilities.
  • Blocking IDO1 is protective against both of these two different pathologies, Aβ protein and tau protein. In addition, IDO1 may also be associated with diseases with other types of pathology, such as Parkinson's disease, as well as a broad spectrum of progressive neurodegenerative diseases known as tauopathies.

Inhibition of the IDO1 enzyme, which blocks its mediated conversion of TRP to KYN, rescued hippocampal memory function in a mouse model of AD by restoring astrocyte metabolism. Aβ proteins and tau proteins activate IDO1 in astrocytes, increasing KYN and inhibiting glycolysis in an aromatic hydrocarbon receptor-dependent manner. Inhibition of IDO1 improves glucose metabolism in the hippocampus and rescues long-term enhancement of the hippocampus in a model of Aβ protein and tau protein pathology. In astrocyte and neuronal co-cultures from KYN patients, inhibition of IDO1 increased the ability of astrocytes to produce lactate and be taken up by neurons.

Targeting PNS in Tumors

Recent research has been exploring the connection between cancer therapies and neurodegenerative diseases such as AD. One such area of interest involves the repurposing of anti-cancer drugs, particularly those targeting growth factors and cancer pathways, to find potential treatments for AD. Here are some key research points regarding this topic.

  • Mechanistic Overlap: Some molecular mechanisms and signaling pathways involved in cancer share similarities with those involved in AD. For example, neuroinflammation and oxidative stress are critical in both conditions.
  • Potential Candidates: Certain anti-cancer compounds such as those that affect the mTOR pathway have shown promise in both extending lifespan in models of aging and reducing amyloid pathology in models of AD.
  • Drug Repurposing: Researchers are investigating existing anti-cancer drugs for their neuroprotective effects. For instance, drugs that inhibit certain cancer pathways may also modify pathways dysregulated in AD, helping to mitigate neurodegeneration.

The search for effective treatments for AD continues to evolve, and the exploration of anti-cancer drugs offers hope for new therapeutic options. Further research, particularly in clinical trials, will be crucial to establish the efficacy and safety of such approaches in Alzheimer's patients.

For Research Use Only. Not For Clinical Use.
Support
Hot Products
Fill out this form for a quote Inquiry Form Send Inquiry
webinar

The Spectrum of Stem Cell-Based Neuronal Models and Their Fit for Purpose

2:00 PM–3:00 PM EST, December 12, 2024

REGISTER NOW
Inquiry Basket
compare

Send inquiry